Rich Pharmaceuticals, Inc - RCHA

Rich Pharmaceuticals, Inc. operates as a biopharmaceutical company. It is developing RP-323 for the treatment of hodgkin’s lymphoma, acute myelogenous leukemia, and to cause elevation of white blood cells. The company was formerly known as Nepia Inc. and changed its name to Rich Pharmaceuticals, Inc., in August 2013. Rich Pharmaceuticals, Inc. was incorporated in 2010 and is based in Beverly Hills, California.